CSL reported net income after tax of $2.04 billion in the first half of 2024/2025. Dr. Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans."
More information you will find here.
